Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) Chairman Neil Desai sold 17,772 shares of Aadi Bioscience stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $2.31, for a total transaction of $41,053.32. Following the transaction, the chairman now directly owns 1,393,771 shares of the company's stock, valued at $3,219,611.01. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Neil Desai also recently made the following trade(s):
- On Monday, March 4th, Neil Desai sold 14,964 shares of Aadi Bioscience stock. The stock was sold at an average price of $2.10, for a total transaction of $31,424.40.
- On Friday, March 1st, Neil Desai sold 27,036 shares of Aadi Bioscience stock. The stock was sold at an average price of $1.97, for a total transaction of $53,260.92.
- On Thursday, February 1st, Neil Desai sold 42,000 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.74, for a total transaction of $73,080.00.
Aadi Bioscience Stock Up 0.5 %
Shares of NASDAQ AADI opened at $2.19 on Thursday. The firm has a 50-day simple moving average of $2.01 and a 200-day simple moving average of $3.18. Aadi Bioscience, Inc. has a 52 week low of $1.55 and a 52 week high of $8.65. The stock has a market capitalization of $53.77 million, a price-to-earnings ratio of -0.90 and a beta of 0.62.
Institutional Inflows and Outflows
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing | Ad
“Titan of Tech” Bets Big on Tiny AI Company
He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal…
But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
A number of institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in Aadi Bioscience by 20.1% during the second quarter. JPMorgan Chase & Co. now owns 13,362 shares of the company's stock worth $91,000 after purchasing an additional 2,234 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Aadi Bioscience by 59.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,462 shares of the company's stock valued at $91,000 after acquiring an additional 2,408 shares during the period. Schonfeld Strategic Advisors LLC increased its holdings in shares of Aadi Bioscience by 7.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 39,000 shares of the company's stock valued at $189,000 after acquiring an additional 2,600 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Aadi Bioscience by 21.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 15,538 shares of the company's stock valued at $191,000 after acquiring an additional 2,712 shares during the period. Finally, Legal & General Group Plc purchased a new position in Aadi Bioscience in the 2nd quarter valued at $34,000. Hedge funds and other institutional investors own 52.08% of the company's stock.
Wall Street Analyst Weigh In
AADI has been the subject of several recent analyst reports. HC Wainwright lowered shares of Aadi Bioscience from a "buy" rating to a "neutral" rating in a research note on Friday, December 15th. Piper Sandler lowered their price target on shares of Aadi Bioscience from $30.00 to $5.00 and set an "overweight" rating on the stock in a report on Friday, December 15th.
View Our Latest Stock Analysis on AADI
About Aadi Bioscience
(
Get Free Report)
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
